Sandoz is shrinking the size of its US footprint as it prioritizes complex generics and biosimilars in the region and divests much of its small molecule generics portfolio to India's Aurobindo. US President Carol Lynch talked about the changing dynamics for the US business and the company's positive outlook for biosimilars in an interview with Generics Bulletin sister publication Scrip at the BIO CEO & Investor conference in New York on 10 February.
"We are looking forward to closing the transaction and when that's behind us, then obviously we've got a smaller business in terms of the areas we are focusing on, but also a smaller company as well to support that," Lynch said